Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.
about
Overactive bladder: strategies to ensure treatment compliance and adherencePersistence and compliance with medication management in the treatment of overactive bladderThe efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladderReal life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in SpainCost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.A novel approach to overactive bladder syndrome treatment.Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)Effect of electroacupuncture versus pelvic floor muscle training plus solifenacin for moderate and severe mixed urinary incontinence in women: a study protocol.Medication adherence in the management of nocturia: challenges and solutions.Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trialValidation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder.Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands.Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in CanadaThe Burden of Overactive Bladder on US Public HealthEfficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns AnalyzerOnabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.Important drug–drug interactions for treatments that target overactive bladder syndrome.The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis.Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects.Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.Tolterodine to relieve urinary symptoms following transurethral resection of the prostate: a double-blind placebo-controlled randomized clinical trial.Self-assessment of treatment compliance with antimuscarinic drugs and lower urinary tract condition among women with urinary incontinence.Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).Current and future pharmacotherapy for treating overactive bladder.Persistence with medication and overactive bladder: an ongoing challenge.Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.An overview of urinary incontinence.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.Fesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physicians.Mechanisms of inhibitory action of TRK-130 (Naltalimide), a μ-opioid receptor partial agonist, on the micturition reflex.The fatty acid amide hydrolase inhibitor oleoyl ethyl amide counteracts bladder overactivity in female rats.
P2860
Q26746914-BA7639CC-D72A-49D6-8B8F-7BFF3677C24DQ26765014-05577193-E74C-450E-80F9-D175845FF492Q26770419-59D86EF3-C8F5-40D5-8466-7A0D96ABF2C0Q33560320-9E0AC8A7-78A4-47FF-BD23-A23203FEB8B8Q33588346-C72AEF4A-1E9D-4C83-9428-D771732C89E1Q33696642-CE0F8920-FBD9-41B6-9D3C-EE3DA557FAACQ33819974-87A831B2-ED2A-4E2D-9BB2-C7F4F136E357Q33835874-2317663A-337B-4540-8518-32FC99A01483Q34079127-A95A829D-0BD8-486B-9048-26CB0E3D656BQ34982181-65E23C69-C05E-4976-83CA-FDADDDAB2BA9Q34991783-B853963C-1F59-4D6F-8EEF-512558E4A912Q35572326-11571CC1-E0C2-46BD-8380-94464BF562DBQ35794880-E30A6E24-E670-4979-B8C1-DCCE21AC4C0EQ36326096-835C4B06-5EFD-4D21-AEE8-11BEBAAABB47Q36767014-6F36FD6E-B225-4314-ABA3-C01505C08833Q36804908-631BA520-3E22-460D-A7FC-A9D0A3D63F14Q37441427-997EC66E-84D4-4343-986F-88A6EE44C5CCQ38031284-0CDAA671-469F-4B59-8CCC-DDD2E486727DQ38032608-56D91237-E8A3-4D7E-9669-88593CF0F782Q38162704-D8CB2DF0-50AF-4BAD-A18B-2BC842238E42Q38200003-9D58590F-EBFA-4F71-8B3D-FDAC91D2C6C9Q38217760-060E9516-67B2-4C38-A484-9827BC84938CQ38338125-21B40EAF-DA30-49B4-B2EC-52D4A78C0A87Q38570412-E052F2DC-83FE-4BC4-A8E2-649CDF211B8AQ38649685-EBA4F336-CFE3-46AE-A84E-8CF8735C3AA9Q38669033-F45FF569-1DA6-427E-9EEF-437B08231A71Q38711099-D7BF7163-5EA3-43FC-BC47-1F84283DFB8AQ38780098-231DCE59-0862-4719-9495-833FA277A9F7Q38827514-6BBEDF00-ED79-4307-80E6-C6AAAA9FA2D5Q38832902-03958389-051B-4CF5-8D70-06A4131F57EBQ38851523-FCD26FCF-9907-48F7-AC7B-1B6C372A0CAEQ38870480-89D7CADD-15C2-4172-9F26-817F40BF0DA9Q38911819-B372746D-DFD3-43B2-BA68-78F172FFCEABQ38979414-8C599DE5-15A4-4E9B-BF9D-842146FBBF2CQ39046374-7642E8E7-F5B0-4E65-A11A-EA2AED9AB4FCQ39475700-1894D891-3C32-46E3-BFDB-6B25AFDC72E0Q40321896-F5AD161C-2767-456D-AB83-47F16CC35363Q42665431-DD8A846E-58D5-4BC0-8C01-8D798D47C03EQ44342688-48085B49-EDA5-49EA-A778-063A54939B89Q45746097-D612A475-C46C-41C6-BE4C-89AA1BBCCCB7
P2860
Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Persistence and adherence in t ...... atic review of the literature.
@en
Persistence and adherence in t ...... atic review of the literature.
@nl
type
label
Persistence and adherence in t ...... atic review of the literature.
@en
Persistence and adherence in t ...... atic review of the literature.
@nl
prefLabel
Persistence and adherence in t ...... atic review of the literature.
@en
Persistence and adherence in t ...... atic review of the literature.
@nl
P2093
P2860
P1476
Persistence and adherence in t ...... atic review of the literature.
@en
P2093
C C Sexton
C Maroulis
D Subramanian
R R Dmochowski
P2860
P304
P356
10.1111/J.1742-1241.2010.02626.X
P577
2011-05-01T00:00:00Z